MYO
ANALYST COVERAGE8 analysts
BUY
+27.8%upside to target
Buy
788%
Hold
113%
7 Buy (88%)1 Hold (13%)0 Sell (-1%)
Full report →
PRICE
Prev Close
0.84
Open
0.86
Day Range0.84 – 0.89
0.84
0.89
52W Range0.61 – 3.45
0.61
3.45
9% of range
VOLUME & SIZE
Avg Volume
373.5K
FUNDAMENTALS
P/E Ratio
-2.4x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.93
Market-like
TECHNICAL
RSI (14)
58
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 20
DEx-Dividend
In 90 days
Aug 17
PDividend Pay
In 97 days
Aug 24
Key MetricsTTM
Market Cap$31.94M
Revenue TTM$41.21M
Net Income TTM-$15.12M
Free Cash Flow-$17.34M
Gross Margin66.0%
Operating Margin-34.1%
Net Margin-36.7%
Return on Equity-114.9%
Return on Assets-41.1%
Debt / Equity2.11
Current Ratio2.73
EPS TTM$-0.36

MYO News

About

myomo's mission is to enable individuals to overcome their paralysis by providing innovative, myoelectric orthotics and support services. we are committed to working with healthcare professionals to deliver high quality outcomes and patient satisfaction through research collaborations and continuing education programs. the company empowers persons with a neuromuscular disability to perform functional activities at home, at work, and in the community, resulting in an improved quality of life and lower healthcare costs.

Industry
Surgical and Medical Instrument Manufacturing
CEO
Paul Gudonis
Harry KovelmanChief Medical Officer
Colin AndersonGlobal Director of Operations
David A. HenryChief Financial Officer
Malcolm G. BockVice President of Engineering & Product Strategy
Micah J. MitchellChief Commercial Officer
Paul R. GudonisPresident, Chief Executive Officer & Chairman
Galina ShtivelmanSenior Director of Human Resources
Kathy SawyersSr. Director of Clinical Outcomes